

DAFTAR PUSTAKA

1. Aziz FM, Andrijono, Saifuddin BA. Buku acuan nasional onkologi ginekologi. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo; 2010
2. European Society for Medical Oncology (ESMO). Cervical cancer.2012.
3. Bruni L, Barrionuevo-Rosas L, Alberto G, Serrano B, Mena M, Gómez D, et al. Human Papillomavirus and Related Diseases Report. Barcelona
4. GLOBOCAN (2018). Cancer today. International Agency for Research on Cancer.
5. Desen, Wan. Buku Ajar Onkologi Klinis Edisi ke-2. Jakarta : Penerbit Fakultas Kedokteran Universitas Indonesia. 2008
6. ICO/IARC HPV Information Centre. Human Papillomavirus and Related Diseases in Asia. HPV Inf Cent. 2018;1-155.
7. Agustina DR, Nurcahyanti. Cervical Cancer : The Case in Indonesia and Natural Product- Based Therapy. J Cancer Biol Res. 2016
8. WHO. Indonesia Global Cancer Observatory . International Agency for Research on Cancer. 2018
9. Yanti YN. Gambaran Faktor Resiko Kejadian Kanker Serviks di RSUP Dr. M. Djamil Padang. J Kesehat Andalas. 2018;1–17.
10. Bidus M.A. dan Elkas J.C. (2007) Cervical and vaginal cancer, dalam Berek's & Novak's Gynecology (editor Berek J.S), edisi ke-14, hal. 1403- 1456, Lippincott Williams & Wilkins, USA
11. Sardi JE, Giaroli A, Sananes C. Long term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage IB squamous carcinoma of the cervix the final results. Gynecol oncol 1997 Oct, 67(1); 61-9.
12. Mabuchi S, Kawano M, Sasano T, Kuroda H. Management of early-stage and locally advanced cervical cancer. In: Shoupe D. Handbook of gynecology. Switzerland: Springer. 2016. P1-9
13. Moore DH. Review: Neoadjuvant chemotherapy for cervical cancer. Expert Opin. Pharmacother. 2003;4:859-67
14. Kwok C. Management of side effects from chemotherapy. The Hongkong anti cancer society. 2010;12:201–11

15. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Kanker Serviks. Kom Penanggulangan Kanker Nas. 2017 : 13
16. Markman M. Chemotherapy in the management of cervix cancer, dalam What.2006
17. Gonzalez-Martin A, LucisGonzalez-Zirtijo L, Carballo N, Garcia JF, Lapuente F, Rojo A dan Chiva LM. The Current role of neoadjuvant chemotherapy in the management of cervical carcinoma. *Gynecolol Oncol* 110. 2009;h:46-40
18. Lapresa M, Parma G, Portuesi R, Colombo N. Neoadjuvant Chemotherapy in Cervical Cancer: An update. *Expert Rev Anticancer Ther.* 2015;15(10):1171-81.
19. Shasha. The Negative Impact of Anemia on Radiotherapy and Chemoradiation Outcomes. *Seminars in Hematology*,2001;38:8-15
20. Kaneyasu Y, Okawa MK, Okawa T. Clinical Evaluation of Chemoradiotherapy for Advanced Cervical Cancer. *Gan To Kagaku Ryoho* 1997;24;2084-91
21. Vaupel, P. The role of hypoxia- induced factors in tumor progression. *Oncologist*.9..2004;.5:10–17.
22. Hardianto, R., Huda., N., & J.Gambaran Indeks Masa Tubuh Pada Pasien Kanker yang Menjalani Kemoterapi,2015;2,1-8
23. Hariani R. Kecukupan Nutrisi Pada Pasien Kanker. *Indonesian Journal Of Cancer*.2007;4:140-143
24. Prayetni. Gambaran umum kanker leher rahim.2007 Diperoleh pada tanggal 10 Juni 2008
25. Rasjidi, I. Vaksin human papilloma virus dan eradikasi Kanker mulut rahim. Surabaya: FKU Brawijaya. 2007
26. Pandey U, Bansal P. What is Cervical Cancer?. *Journal Gynecology and Women`s Health.* March 2017; 2(5).
27. Handayani L, Medi M, Suharmiati, Ayunungtyas A. Penatalaksanaan Kanker Serviks. Menaklukkan Kanker Serviks dan Kanker Payudara dengan 3 Terapi Alami. Jakarta. PT AgroMedia Pustaka. 2013; 7-17
28. Riset Kesehatan Dasar (Riskesdas) (2018). Badan Penelitian dan Pengembangan Kesehatan Kementerian RI tahun 2018. Darmawati. Kanker Serviks Wanita Usia Subur. *Idea Nurs J.* 2007;1(1):9– 14.

29. Sasmita N. Frekuensi karsinoma serviks di laboratorium patologi anatomi Fakultas Kedokteran Universitas Andalas periode januari 2001 - desember 2004 (skripsi). Padang: Fakultas Kedokteran Universitas Andalas; 2005
30. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. HPV in the etiology of human cancer. *Vaccine* 2006;24:1-10
31. Parkin DM, Bray F. The burden of HPV-related cancers. *Vaccine* 2006;24:11-
32. Kaufman RH, Adam E, Vonka V. Human Papillomavirus infection and cervical carcinoma. *Clin Obstet and Gynecol* 2000;43:363- 80
33. Shin B, Dubeau L. Cell cycle abnormalities in squamous cell carcinoma of the cervix. *CME Journal of Gynecologic Oncology* 2001;6:167:72
34. Cheung TH, Chung TKH, Lo KWK, et al. Apoptosis-Related Proteins in Cervical Intraepithelial Neoplasia and Squamous Cell carcinoma of the Cervix. *Gynecol Oncol* 2002;86:14-8.
35. Rahayu AS. Infeksi Human Papilloma Virus (HPV) dan Pencegahannya pada Remaja dan Dewasa Muda. *Journal Biologi Papua*. Oktober 2010; 2(2):81-88
36. Wardhani H, Moetmainnah S, Yazid N. Hubungan Kejadian Carcinoma Cervicis Uteri dengan Umur, Status Perkawinan, dan Paritas di RSUP Dr Kariadi Semarang Periode Januari – Maret 2011. *Jurnal Kedokteran Muhammadiyah*. 2013; 1(2).
37. Prandana DA, Rusda M. Pasien Kanker Serviks di RSUP H. Adam Malik Medan Tahun 2011. *E-Jurnal FK USU*. 2013; 1(2)
38. Wiknjosastro H. Ilmu Kebidanan. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo; 2007.
39. Rasjidi I. Manual Prakanker Serviks. 1st ed. Jakarta: Sagung Seto; 2008.
40. Darmayanti, Hapisah, Kirana R. Faktor-faktor yang Berhubungan dengan Kanker Leher Rahim di RSUD Ulin Banjarmasin. *Jurnal Kesehatan*. Oktober 2015; 6(2)
41. Saputra A. Analisis Resiko dari FaktorFaktor Predisposisi Penderita Kanker Leher Rahim. Universitas Sumatera Utara; 2012. p. 4–16.
42. Ali, A, H,. Kontrasepsi Hormonal. Jakarta . YBP-SP. Glasier. 2002
43. Lax S. Histopathology of cervical precursor lesions and cancer. *Acta Dermatovenerologica Alpina, Pannonica Adriat*. 2011;20(3):125–33.
44. Elizabeth. Cegah kanker pada wanita. Jakarta: EGC.2001

45. Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging : ompact on cancer management and decision making, part I. *Cancer J*. 2005;11:449-460
46. Ades F, Yamaguchi N. WHO, RECIST, and immune-related response criteria: Is it time to revisit pembrolizumab results? *Ecancermedalscience*. 2015;9(604):1-4.
47. Peterson LL, Hurria A, Feng T, Mohile SG, Owusu C, Klepin HD, et al. Association between renal function and chemotherapy-related toxicity in older adults with cancer. *J Geriatr Oncol*. 2017 March; 8(2): 96-101.
48. Jerome K, Hurria A. Determining chemotherapy tolerance in older patients with cancer. *J Natl Compr Canc Netw*. 2013 December; 11(12): 1494-1502.
49. Leo C, Giaccia AJ, Denko NC. The hypoxic tumor microenvironment and gene expression. *Semin. Radiat. Oncol*. 2004; 14:207-14.
50. Fuso L, Mazzola S, Marocco F, et al. Pretreatment Serum Hemoglobin Level as A Predictive Factor of Response To Neoadjuvant Chemotherapy in Patients With Locally Advanced Squamous Cervical Carcinoma : A Preliminary Report. 2005;99.
51. Vaupel, P, Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. *Transfus. Clin. Biol*. 2005; 12:5-10.
52. Kirshner J, Hatch M, Hennessy DD, Fridman M, Tannous RE. Anemia in stage II and II breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy. *The Oncologist* 2004; 9: 25-32.
53. Mercadante S, Gebbia V, Marrazzo A. Anemia in cancer: pathophysiology and treatment. *Cancer Treat Rev*. 2000 Aug; 26(4): 303-11.
54. Susilowati. Pengukuran status gizi dengan antropometri gizi[home page on internet]. Cimahi: Sekolah Tinggi Ilmu Kesehatan Ahmad Yani; c2008[update 2008; cited 2009 Okt 23].
55. Supariasa I, Bakri B, Fajar I. *Penilaian Status Gizi*. Jakarta : Penerbit EGC. 2002
56. Mirzana I. *Asupan Energi, Protein dan Status Gizi pada Pasien Kanker Serviks dengan Terapi Kemoradiasi*. Skripsi. Semarang : Universitas Diponegoro. 2008
57. Madiyono B, Mz SM, Sastroasmoro S, Budiman I, Purwanto SH. Perkiraan besar sampel. In: Sastroasmoro S, editor. *Dasar - dasar Metodologi Penelitian Klinis*. 5th ed. Jakarta: Sagung Seto; 2014. p. 355.

58. Nurul Nadia. Korelasi Stadium dengan Usia Penderita Kanker Serviks di Departemen Patologi Anatomi RSCM Tahun 2007. Jakarta. Universitas Indonesia.2007
59. Latifah SR. Hubungan Stadium Klinis dengan Derajat Diferensiasi Sel pada Pasien Karsinoma Sel Skuamosa Serviks di RSUD Abdul Moeloek Bandar Lampung. 2017
60. Schwartz PE, Merino MJ, Curnen MGM. Clinical management of patient with invasive cervical cancer following a negative pap smear. Yale J of Biology and Medicine [PMC2590273].1988
61. Ma Y, Zhao G, Qi J, et al. Neoadjuvant Brachytherapy and Chemotherapy Followed by Radical Surgery for Stage IB2 and IIA Cervical Cancer: A Retrospective Comparison with Chemoirradiation. Mol Clin Oncol. 2018;617-22.
62. Icazar JL, Jurado M, Lopez-García G. Tumor Vascularization in Cervical Cancer by 3-Dimensional Power Doppler Angiography Correlation With Tumor Characteristics. Int J Gynecol Cancer. 2010;20(3):393-7.
63. World Health Organization. *Comprehensive Cervical Cancer Prevention And Control: A Healthier Future For Girls And Women. Switzerland: 2013. p:2-3*
64. Edianto D. Kanker Serviks. Dalam: Aziz M.F, Andrijono, Saiffudin, editor. Onkologi Ginekologi: Buku Acuan Nasional. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo. 2006; hal: 443-45
65. Kumar V, Robbins S. Neoplasma dalam Buku Ajar Patologi. Ed 7. Kumar V, Robbins S, editor. Jakarta: EGC. 2012; h:186-91
66. Herlana F, Nur IM, Purbaningsih W. Karakteristik Pasien Kanker Serviks berdasar atas Usia , Paritas , dan Gambaran Histopatologi di RSUD Al-Ihsan Bandung Characteristics of Cervical Cancer Patients base on Age , Parity , and Histopathologic Pattern in Al-Ihsan Bandung Regional Hospital. 2017;1(22):138-42.
67. Endo D, Todo Y, Okamoto K, Minobe S, Kato H, Nishiyama N. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy : a retrospective analysis in a Japanese cohort. J Gynecol Oncol. 2014;26(1):12-8.

68. Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Lopez C, et al. Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery. 2017;27(3):514–22.
69. Fajriah RA. Distribusi Gambaran Histopatologi Pasien Kanker Serviks Uteri di RSUD Dr. Zainoel Abidin Banda Aceh. 2013;13:1–5.
70. Shen Y, Yang L, Wang Z. Treatment of Early Bulky Cervical Cancer with Neoadjuvant Paclitaxel, Carboplatin and Cisplatin Prior to Laparoscopic Radical Hysterectomy and Pelvic Lymphadenectomy. *Oncol Lett.* 2012;3(3):641-5.
71. Couvreur K, Naert E, Jaeghere E De, Tummers P, Makar A, Visschere P De, et al. Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates. 2018;1–10.
72. Quinn MA, Benedet JL, Odicino F, Beller U, Maisonneuve P, Creasman WT, et al. Carcinoma of the cervix uteri. *Int J of Gynecol and Obstet.* 2006;95:543-103.
73. Fatimah AN, Studi Kualitatif Tentang Perilaku Keterlambatan Pasien Dalam Melakukan Pemeriksaan Ulang Pap Smear di Klinik Keluarga Yayasan Kusuma Buana Tanjung Priuk Jakarta Tahun 2008, Skripsi, Jurusan Kesehatan Masyarakat Fakultas Ilmu Kesehatan, Universitas Indonesia. 2009.
74. Yang L, Guo J, Shen Y, et al. Clinical Efficacy and Safety of Paclitaxel Plus Carboplatin as Neoadjuvant Chemotherapy Prior to Radical Hysterectomy and Pelvic Lymphadenectomy for Stage IB 2 -IIB Cervical Cancer. 2015;8(8):13690-8.
75. Setyarini E. Faktor-Faktor Yang Berhubungan Dengan Kejadian Kanker Leher Rahim di RSUD Dr Moewardi Surakarta, Skripsi, Jurusan Kesehatan Masyarakat Fakultas Ilmu Kesehatan, Universitas Muhamadyah Surakarta. 2009
76. Reis N, Beji NK, Kilic D. Risk Factors for Cervical Cancer: Results from a Hospital- Based Case-Control Study. *International Journal of Hematology and Oncology UHOD.* 2011 3(21).

77. Center for disease control and prevention. HPV–Associated Cancer- United States. 2004–2008. MMWR Morb Mortal Wkly Rep 2012 61(15);258-261
78. Annisa Rachmawati. Hubungan Kadar Hemoglobin dengan Respon Tumor Pada Pasien Kanker Serviks yang Mendapat Terapi Radiasi di RSUP Dr. Sardjito. Yogyakarta : Universitas Gadjah Mada. 2013
79. Fitri N. Pengaruh kadar hemoglobin, kadar hematokrit dan transfusi terhadap respon tumor dan kesintasan penderita kanker serviks stadium lanjut lokal. 2014;(September).
80. Candelaria M, Cetina L, Gonzalez AD. Anemia in Cervical Cancer Patients. Medical Oncology.2005;22:161-168
81. Razeq HN. Cancer –Related Anemia. Saudi Med J. 2004;25(1):15-20.
82. Fyles AW, Pintilie M, et al. Prognostic Factors in Patients with Cervix Cancer Treated by Radiation Therapy: Results of a Multiple Regression Analysis. Radiother Oncol 1995;35:107-117.
83. Thakur P, Seam RK, Gupta MK, Gupta M, Bhattacharyya T, Sharma M. Comparison of Effects of Hemoglobin Levels Upon Tumor Response among Cervical Carcinoma Patients Undergoing Accelerated Hyperfractionated Radiotherapy versus Cisplatin Chemoradiotherapy. 2015;16:4285–9.
84. Jamil K,Parimi R,Kalyani P. Assesment of severity of Anemia and its Effect on the Quality of Life of Patients Suffering with Various Types of Neoplasia.Biology and Medicine.2009;3:63-72
85. Werestandina A. Hubungan Indeks Masa Tubuh (IMT) dengan Respon Klinis Kemoradiasi Pasien Kanker Serviks Stadium III di RSUD Dr. Saiful Anwar Malang. Skripsi. Malang : Universitas Brawijaya. 2013
86. Zulkarnain AK. Perbedaan Indeks Massa Tubuh Pasien Ca Mammae Duktus Infiltratif Sebelum dan Sesudah Mendapat Terapi Neoadjuvant. Skripsi . Semarang:Universitas Diponegoro